

AdVance™ XP Male Sling System

Patient selection criteria¹

Six (6) patient selection criteria for the AdVance XP Male Sling (post-prostatectomy incontinence):

1. <4 pads/day or <300g daily pad weight
2. Intact appearing external urinary sphincter without segmental defects on cystoscopy; ability to volitionally contract their external urinary sphincter
3. No history of pelvic radiation or cryotherapy
4. No history of previous surgical procedures to treat incontinence
5. Volitional detrusor contraction when voiding
6. Post-void residual (PVR) urine volume <100 mL

	Patient meets all 6 criteria	Patient does not meet all 6 criteria	P value
N=95	72	23	
Mean daily preoperative pad use (range)	2.6 (1-4)	4.4 (1-9)	<.05
Mean daily preoperative pad weight, g (range)	131 (10-280)	520 (80-1200)	<.05
Mean daily postoperative pad use (range)	0.6 (0-6)	2.4 (0-7)	<.05
Mean daily postoperative pad weight, g (range)	16 (0-310)	201 (0-800)	<.05
Pad reduction percentage	77%	45%	
Pad weight reduction percentage	88%	61%	
Patient satisfaction	92%	30%	

Mean follow-up: 28 months

1. Sturm RM, Guralnick ML, Stone AR, et al. Comparison of clinical outcomes between "ideal" and "nonideal" transobturator male sling patients for treatment of postprostatectomy incontinence. *Urology*. 2014 May;83(5):1186-8.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.

The AdVance™ XP Male Sling System is intended for the placement of a suburethral sling for the treatment of male stress urinary incontinence (SUI). These devices are contraindicated for patients with urinary tract infections, blood coagulation disorders, a compromised immune system or any other condition that would compromise healing, with renal insufficiency, and upper urinary tract relative obstruction. Possible adverse events include, but are not limited to, urinary retention, return to incontinence and pain. MH-557013-AA.

All trademarks are the property of their respective owners.